Low molecular weight biomarkers in the nephrotoxicity;Niskocza̧steczkowe wskaźniki biochemiczne w diagnostyce nefrotoksyczności

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 6, 2006, Pages 1129-1138

  Marchewka, Zofia ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Early markers; Nephrotoxicity; Urine analysis

Indexed keywords

ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; BIOCHEMICAL MARKER; CLARA CELL PROTEIN; CYSTATIN C; LIPOCALIN; LIPOCORTIN 5; LYSOZYME; RETINOL BINDING PROTEIN; XENOBIOTIC AGENT;

DIAGNOSTIC VALUE; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE; MOLECULAR WEIGHT; NEPHROTOXICITY; PROTEIN URINE LEVEL; REVIEW;

EID: 33846686497     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Sancewicz-Pach K, Ogarek I: Leki i substancje potencjalnie nefrotoksyczne. Przegl Lek 2001, 58, 4, 186-190.
2. Klaassen CD: Casarett & Doull's toxicology, The Basic Science of Poisons. International Edition, New York 1996, 14, 426-432.
3. Kopeć M: Udział aneksyn w regulacji krzepniecia krwi i fibrynolizy. Acta Haematol Pol 1998, 29, 2, 147-155.
4. Zabek J, Wojciechowska B, Alekberova Z, Reshetniak T, Biernacka E, Nasonova V, Karlik W: Przeciwciała dla aneksyny V jako nowy wskaźnik ryzyka zakrzepic i poronień w toczniu rumieniowatym układowym (SLE) oraz w zespole antyfosfolipidowym pierwotnym (PAPS) i wtórnym (SAPS). Reumatologia 2003, 41, 1, 12-24.
5. Matsuda R, Kaneko N, Horikawa Y, Chiwaki F, Shinozaki M, Ieiri T, Suzuki T, Ogawa N' Localization of annexin V in rat normal kidney and experimental glomemlonephritis. Res Exp Med 2001, 200, 2, 77-92.
6. Matsuda R, Kaneko N, Horikawa Y, Chiwaki F, Shinozaki M, Abe S, Yumura W, Nihei H, Ieiri T: Measurement of urinary annexin V by ELISA and its significance as a new urinary-marker of kidney disease. Clin Chim Acta 2000, 298, 29-43.
7. Bengtsson AA, Sturfelt G, Gullstrand B, Truedsson L: Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus - an additional mechanism to increased autoantigen load? Clin Exp Immunol 2004, 135, 535-543.
8. 1-microglobulin by hemoglobin induces heme-binding and heme-degradation properties. Blood 2002, 99, 6, 1894-1901.
9. 1-microglobulin: a yellow-brown lipokalin. Biochim Biophys Acta 2000, 1482, 172-174.
10. Mantur M, Kemona H, Da̧browska M, Da̧browska J, Sobolewski S, Prokopowicz J: Alpha1-microglobulin as a marker of proximal tubular damage in urinary tract infection in children. Clin Nephrol 2000, 53, 4, 283-287.
11. Hong CY, Hughes K, Chia KS, Ng V, Ling SL: Urinary alphal-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapure. Diabetes Care 2003, 26, 338-341.
12. 1-microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients. Clin Chim Acta 2000, 297, 93-102.
13. Moriguchi J, Ezaki T, Tsukahara T, Furuki K, Fukui Y, Okamoto S, Ukai H, Sakurai H, Stumbo S, Ikeda M: Comparative evaluation of four urinary tubular dysfunction markers witb special references of aging and correction for creatinine concentration. Toxicol Lett 2003, 143, 279-290.
14. 1-microglobulin excretion as biomarker of renal toxicity in trichloroethylene-exposed persons. Int Arch Occup Environ Heath 2004, 77, 186-190.
15. Bernard A, Lauwerys R: Low-molecular-weight proteins as markers of organ toxicity with special reference to Clara cell protein. Toxicol Lett 1995, 77, 145-151.
16. Bernard AM, Thielemans NO, Lauwerys RR: Urinary protein 1 or Clara cell protein: a new sensitive marker of proximal tubular dysfunction. Kidney Int 1994, 47, 34-37.
17. Shijubo N, Kawabata I, Sato N, Itoh Y: Clinical Aspects of Clara Cell 10-kDa Protein/Uteroglobin (Secretoglobin 1A1). Curr Pharm Des 2003, 9, 14, 1139-1149.
18. Raghu P, Ravinder P, Sivakumar B: A new method for purification of human plasma retinol-binding protein and transthyretin. Biotechnol Appl Biochem 2003, 38, 19-24.
19. Yamada K, Matsuoka Y, Yamamoto A, Kawana T, Ishii K, Ishimi Y, Ikegami S: Elevation of plasma retinol binding protein concentration in experimental acute renal failure. Nutr Res 1997, 17, 10, 1555-1567.
20. Sundaram M, Aalten D, Findlay J, Sivaprasadarao A: The transfer of transthyretin and receptor-binding properties from the plasma retinol-binding protein to the epididymal retinoic acid-binding protein. Biochem J 2002, 362, 265-269.
21. Camara NO, Silva MS, Nishida S, Pereira AB, Pacheco-Silva A: Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renalgraft survival. Transplantation 2004, 78, 269-275.
22. Kirsztajn GM, Nishida SK, Silva MS, Azjen H, Pereira AB: Urinary retinol binding protein as a prognostic marker in the treatment of nephrotic syndrome. Nephron 2000, 86, 109-114.
23. Bang LE, Holm J, Svendsen T: Retinol-Binding Protein and Transferrin in Urine. New Markesr of Renal Function in Essential Hypertension and White Coat Hypertension? Am J Hypertens 1996, 9, 1024-1028.
24. Buchet JP, Heilier JF, Bernard A, Lison D, Jin T, Wu X, Kong Q, Nordberg G: Urinary protein excretion in humans exposed to arsenic and cadmium. Int Arch Occup Environ Health 2003, 76(2), 111-120.
25. de Burbure C, Buchet JP, Bernard A, Leroyer A, Nisse C, Haguenoer JM, Bergamaschi E, Mutti A: Biomarkers of renal effects in children and adults with low environmental exposure to heavy metals. J Toxicol Environ Health A 2003, 66, 783-798.
26. Weaver VM, Lee BK, Todd AC, Jaar BG, Ahn KD, Wen J, Shi W, Parsons PJ, Schwartz BS: Associations of patella lead and other lead biomarkers with renal function in lead workers. J Occup Envirin Med 2005, 47, 235-243.
27. Voss JU, Roller M, Brinkmann E, Mangelsdorf I: Nephrotoxicity of organic solvents: biomarkers for early detection. Int Arch Occup Environ Health 2005, 78, 475-485.
28. 2-mikroglobinuria u dzieci z odplywami pecherzowo-moczowymi i nawracaja̧cymi zakażeniami układu moczowego. Pol Merk Lek 2000, 8, 240-241.
29. 2-mikroglobuliny w diagnostyce i terapii. Postepy Hig Med Dośw 1998, 52, 507-514.
30. Kuźniar J, Marchewka Z, Krasnowski R, Długosz A, Klinger M: Wykorzystanie wydalania w moczu bialek drobnoczzsteczkowych oraz enzymów jako wskaźników uszkodzenia śródmia̧ższowego w glomerulopatiach. Adv Clin Exp Med 2003, 12, 305-313.
31. 2-mikroglobulinuria in the assessment of the influence of proteinuria on the progression of glomerulopathies. Int Urol Nephrol 2001, 33, 673-676.
32. Marchewka Z: Wartość diagnostyczna transferaz glutationowych i innych parametrów biochemicznych w moczu jako wczesnych wskaźéników uszkodzenia nerek. Diagn Lab 2004, 40, 567-572.
33. Marchewka Z, Dtugosz A: Wybrane wskaźniki biochemiczne w moczu w ocenie funkcji nerki pracowników narażonych na benzynȩ. Bromat Chem Toksykol 2003, 36, 155-159.
34. Warwas M, Murawska E: Ludzka cystatyna C. Diagn Lab 1991, 27, 71-73.
35. Filler G, Bokenkamp A, Hofman W, Le Bricon T, Martinez-Bru C, Grubb A: Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem 2005, 38, 1-8.
36. Grubb A: Cystatin C-Properties and use as diagnostic marker. Adv Clin Chem 2001, 35, 64-91.
37. Mussap M, Plebani M: Biochemistry and Clinical Role of Human Cystatin C. Crit Rev Clin Lab Sci 2004, 41, 467-550.
38. Bardi E, Bobok I, Olah VA, Olah E, Kappelmayer J, Kiss C: Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatr Nephrol 2004, 19, 1145-1147.
39. Piwowar A, Warwas M: Cystatyna C jako wskaźnik przesatczania kłebuszkowego nerek. Postepy Hig Med Dosw 2001, 55, 687-695.
40. Uchida K, Gotoh A: Measurement of cystatin-C and creatinine in urine. Clin Chim Acta 2002, 103, 121-128.
41. Jung K, Mattenheimer H, Burchardt U: Urinary enzymes in clinical and experimental medicine. Springer-Verlag, Berlin 1992.
42. Hrycek A, Szołtysik I, Grzeszczak W: Aktywność lizozymu w surowicy krwi nierozcieńczonej i rozcieńczonej u chorych po przeszczepie nerki leczonych cyklosporyna A z prednizonem lub azatiopryna z prednizonem. Pol Arch Med Wewn 1992, 88, 12-17.
43. Price RG: Early markers of nephrotoxicity. Comp Clin Path 2002, 11, 1-7.
44. Coles M, Diercks T, Muehlenweg B, Bartsch S, Zölzer V, Tschesche H, Kessler H: The Solution Structure and Dynamics of Human Neutrophil Gelatinase Associated Lipocalin. J Mol Biol 1999, 289, 139-140.
45. Flower D: The lipocalin protein family: structure and function. Biochem J 1996, 318, 1-14.
46. Mishra J, Qing MA, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P: Identification of neutrophil gelatoicnase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14, 2534-2539.
47. Xu S, Venge P: Lipocalins as biochemical markers of disease. Biochim Biophys Acta 2000, 1482, 303-304.
48. Mishra J, Dent K, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Sheo M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365, 1231-1238.
49. Mishra J, Mori K, Ma Q, Kelly C, Barasch J: Neutrophil Gelatinase-Associated Lipocalin: A Novel Early Urinary Biomarker for Cisplatin Nephrotoxicity. Am J Nephrol 2004, 24, 307-315.